<SEC-DOCUMENT>0001070081-19-000046.txt : 20190805
<SEC-HEADER>0001070081-19-000046.hdr.sgml : 20190805
<ACCEPTANCE-DATETIME>20190805080946
ACCESSION NUMBER:		0001070081-19-000046
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190804
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190805
DATE AS OF CHANGE:		20190805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		19997608

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-k080519.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sa78707cd1c8e4e6ea7f02d7d91c89a83"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August 4, 2019</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35969</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3416587</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:333px;"></td><td style="width:16px;"></td><td style="width:333px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100 Corporate Court</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South Plainfield, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">07080</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(908) 222-7000</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock, $0.001 par value per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s8de408b887434ef1b967b0f9668a255f"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 4, 2019, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) and Bristol-Myers Squibb Company, (the &#8220;Landlord&#8221;) entered into a Lease Agreement&#160;(the &#8220;Lease&#8221;), relating to the lease&#160;of approximately 185,000 square feet of office, production and laboratory space at a facility located in Hopewell Township, New Jersey (the &#8220;Campus&#8221;).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rental term of the Lease is currently estimated to commence on July 1, 2020 (the &#8220;Commencement Date&#8221;). Upon the Commencement Date, the Lease has an initial term of fifteen years (the &#8220;Initial Term&#8221;), with two consecutive 10-year renewal periods at the Company&#8217;s option. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate rent for the Initial Term will be approximately $88 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the terms of the Lease, the Company has a right of first refusal to rent certain other space within the Campus, which would be triggered upon the Landlord&#8217;s issuance of a second round proposal or letter of intent to another tenant for such space. The Company also may seek to build a new separate building on the Campus, which may not contain less than 75,000 square feet (the &#8220;New Building&#8221;). Upon receipt of notice of the Company&#8217;s intention to build the New Building, the Landlord may, in its sole discretion, construct and lease the New Building to the Company or enter into a ground lease with the Company permitting the Company to construct the New Building. The lease term for the New Building will be fifteen years with two consecutive five-year renewal rights. Rent terms for the New Building will be determined based on the land value, construction and project costs subject to whether the Landlord or Company constructs the New Building. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also obligated to provide the Landlord with either an unconditional, irrevocable and transferable letter of credit (the &#8220;Letter of Credit&#8221;) in the amount of $7,500,000, for a term of not less than five years, as a security deposit, or the same amount as a cash security deposit within thirty days upon entering into the Lease. The Letter of Credit shall remain in effect continuously and shall either expire (i) sixty days after the Expiration Date (as defined in the Lease) or (ii) be automatically self-renewing until the Expiration Date. If the Lease is extended, the Company must continue to provide and maintain the Letter of Credit until sixty days after the extended Expiration Date. If after the fifth anniversary of the Commencement Date, the Company has not received notice of being in default of the Lease, then the Letter of Credit shall be reduced to $3,750,000.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Lease contains customary events of default, representations, warranties and covenants.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing summaries of the Lease and Letter of Credit are not complete and are qualified in their entirety by reference to the Lease and Letter of Credit, which will be filed as exhibits to the Company&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information set forth in or incorporated by referenced into Item 1.01 above is hereby incorporated by reference into this Item 2.03.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2019, the Company issued a press release in which it announced the execution of the Lease. A copy of the press release is attached to this Current Report on Form 8-K (this "Report") as Exhibit 99.1 and is incorporated by reference into this Item 7.01.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information set forth in or incorporated by reference into this Item 7.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:72px;text-indent:-72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex991hopewellpressrelease.htm"><font style="font-family:inherit;font-size:10pt;">Press Release, dated August 5, 2019 issued by PTC Therapeutics, Inc.</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August 5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emily Hill</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991hopewellpressrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6F9FAB301BEB43EB31335FD4870D44E6"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:left;"><img src="ex991hopewellpressrel_image1.gif" alt="ex991hopewellpressrel_image1.gif" style="height:90px;width:150px;"></div><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">PTC Therapeutics Expands Presence in New Jersey by Securing </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">State-of-the-Art Biologics Facility</font></div><div style="line-height:130%;text-align:center;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">- Facility will support gene therapy production and continued development of pipeline of investigational medicines -</font></div><div style="line-height:138%;text-align:center;padding-left:77px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:center;padding-left:53px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">- PTC to gain access to highly-qualified specialists in biologics operations -</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., Aug. 5, 2019 &#8211; </font><font style="font-family:inherit;font-size:11pt;">PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has signed a long-term lease agreement with Bristol-Myers Squibb Company (NYSE: BMY). Under the lease agreement, PTC will gain access to approximately 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, N.J. campus. PTC plans to further develop the biologics facility to support gene therapy production and foster innovation and employment in the community. In addition, PTC plans to move its research operations to a newly renovated building on the same campus. These facilities will complement and enhance existing operations at PTC global headquarters in South Plainfield, N.J.  </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The Hopewell facility is a vital part of our strategy to develop best-in-class therapeutics for patients with high unmet medical need,&#8221; said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;Obtaining this facility allows PTC to execute on our plans of rapidly advancing our gene therapy pipeline. Access to best-in-class technology and highly qualified biologics operation specialists is key for PTC to meet our goal of becoming a leader in gene therapy.&#8221; </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The facility is located on an existing </font><font style="font-family:inherit;font-size:11pt;color:#2e74b5;text-decoration:underline;">BMS property</font><font style="font-family:inherit;font-size:11pt;">&#32;encompassing over a million square feet which BMS is transitioning to a multi-tenant research and development campus. PTC intends to initially dedicate the cGMP suites on the site, which were recently renovated, to produce material to serve multiple pre-clinical and clinical programs, adding to the current pre-clinical production capacity in Bridgewater, N.J. Together with the start-up of the gene therapy development and production operations, PTC plans to relocate and expand its global discovery and research operations to the same site in 2020. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">About PTC Therapeutics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">for patients who have an unmet medical need. To learn more about PTC, please visit us on www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">For More Information: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">Investors: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Emily Hill</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">+1 (908) 912-9327</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;text-decoration:underline;">ehill@ptcbio.com</font><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">&#32;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">Media: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Jane Baj</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">+1 (908) 912-9167</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;text-decoration:underline;">jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC&#8217;s gene therapy platform; expectations with respect to the potential financial impact and benefits of the lease agreement for the Hopewell site; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.  </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: expectations with respect to the potential financial impact or PTC's ability to realize the anticipated benefits of the acquisition of Agilis and its gene therapy platform; expectations with respect to PTC's ability to obtain marketing approval of product candidates acquired from Agilis within the expected time period; PTC&#8217;s ability to effectively utilize the Hopewell site, including with respect to the continued development of gene therapy product candidates; PTC&#8217;s ability to satisfy its obligations under the terms of the lease agreement for the Hopewell site; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including any gene therapy product candidates. </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex991hopewellpressrel_image1.gif
<TEXT>
begin 644 ex991hopewellpressrel_image1.gif
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M7/F?7/F?7?F@70                                   "'Y! $
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CN[([N[1;N[9[N[B;N[J[N[S;N[[[N\ ;O,([O,2K> $! #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
